Your browser doesn't support javascript.
loading
Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors.
Grout, John A; Sirven, Philemon; Leader, Andrew M; Maskey, Shrisha; Hector, Eglantine; Puisieux, Isabelle; Steffan, Fiona; Cheng, Evan; Tung, Navpreet; Maurin, Mathieu; Vaineau, Romain; Karpf, Lea; Plaud, Martin; Begue, Anne-Laure; Ganesh, Koushik; Mesple, Jérémy; Casanova-Acebes, Maria; Tabachnikova, Alexandra; Keerthivasan, Shilpa; Lansky, Alona; Berichel, Jessica Le; Walker, Laura; Rahman, Adeeb H; Gnjatic, Sacha; Girard, Nicolas; Lefevre, Marine; Damotte, Diane; Adam, Julien; Martin, Jerome C; Wolf, Andrea; Flores, Raja M; Beasley, Mary Beth; Pradhan, Rachana; Muller, Soren; Marron, Thomas U; Turley, Shannon J; Merad, Miriam; Kenigsberg, Ephraim; Salmon, Hélène.
Afiliación
  • Grout JA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Sirven P; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Leader AM; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Maskey S; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Hector E; PSL Research University, Paris, France.
  • Puisieux I; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Steffan F; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Cheng E; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Tung N; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Maurin M; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Vaineau R; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Karpf L; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Plaud M; PSL Research University, Paris, France.
  • Begue AL; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Ganesh K; PSL Research University, Paris, France.
  • Mesple J; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Casanova-Acebes M; PSL Research University, Paris, France.
  • Tabachnikova A; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Keerthivasan S; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Lansky A; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Berichel JL; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Walker L; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Rahman AH; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Gnjatic S; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Girard N; PSL Research University, Paris, France.
  • Lefevre M; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Damotte D; PSL Research University, Paris, France.
  • Adam J; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Martin JC; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Wolf A; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Flores RM; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Beasley MB; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Pradhan R; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Muller S; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Marron TU; PSL Research University, Paris, France.
  • Turley SJ; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Merad M; PSL Research University, Paris, France.
  • Kenigsberg E; Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.
  • Salmon H; PSL Research University, Paris, France.
Cancer Discov ; 12(11): 2606-2625, 2022 11 02.
Article en En | MEDLINE | ID: mdl-36027053
ABSTRACT
It is currently accepted that cancer-associated fibroblasts (CAF) participate in T-cell exclusion from tumor nests. To unbiasedly test this, we used single-cell RNA sequencing coupled with multiplex imaging on a large cohort of lung tumors. We identified four main CAF populations, two of which are associated with T-cell exclusion (i) MYH11+αSMA+ CAF, which are present in early-stage tumors and form a single cell layer lining cancer aggregates, and (ii) FAP+αSMA+ CAF, which appear in more advanced tumors and organize in patches within the stroma or in multiple layers around tumor nests. Both populations orchestrate a particular structural tissue organization through dense and aligned fiber deposition compared with T cell-permissive CAF. Yet they produce distinct matrix molecules, including collagen IV (MYH11+αSMA+ CAF) and collagen XI/XII (FAP+αSMA+ CAF). Hereby, we uncovered unique molecular programs of CAF driving T-cell marginalization, whose targeting should increase immunotherapy efficacy in patients bearing T cell-excluded tumors.

SIGNIFICANCE:

The cellular and molecular programs driving T-cell marginalization in solid tumors remain unclear. Here, we describe two CAF populations associated with T-cell exclusion in human lung tumors. We demonstrate the importance of pairing molecular and spatial analysis of the tumor microenvironment, a prerequisite to developing new strategies targeting T cell-excluding CAF. See related commentary by Sherman, p. 2501. This article is highlighted in the In This Issue feature, p. 2483.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibroblastos Asociados al Cáncer / Neoplasias Pulmonares Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibroblastos Asociados al Cáncer / Neoplasias Pulmonares Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article